NCT00504933View on ClinicalTrials.gov

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL

Enrollment

683

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

bilastine

20 mg (encapsulated) tablets QD/14days

DRUG

Cetirizine

10 mg (encapsulated) tablets. QD/14 days

DRUG

Placebo

(encapsulated) Tablets QD/14 days

Sponsors

Lead Sponsor

Faes Farma, S.A.

All Listed Sponsors

lead

Faes Farma, S.A.

INDUSTRY

NCT00504933 - Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter